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Abstract
Background: SecTRAPs (selenium compromised thioredoxin reductase-derived apoptotic proteins) can be formed from the
selenoprotein thioredoxin reductase (TrxR) by targeting of its selenocysteine (Sec) residue with electrophiles, or by its
removal through C-terminal truncation. SecTRAPs are devoid of thioredoxin reductase activity but can induce rapid cell
death in cultured cancer cell lines by a gain of function.
Principal Findings: Both human and rat SecTRAPs killed human A549 and HeLa cells. The cell death displayed both
apoptotic and necrotic features. It did not require novel protein synthesis nor did it show extensive nuclear fragmentation,
but it was attenuated by use of caspase inhibitors. The redox active disulfide/dithiol motif in the N-terminal domain of TrxR
had to be maintained for manifestation of SecTRAP cytotoxicity. Stopped-flow kinetics showed that NADPH can reduce the
FAD moiety in SecTRAPs at similar rates as in native TrxR and purified SecTRAPs could maintain NADPH oxidase activity,
which was accelerated by low molecular weight substrates such as juglone. In a cellular context, SecTRAPs triggered
extensive formation of reactive oxygen species (ROS) and consequently antioxidants could protect against the cell killing by
SecTRAPs.
Conclusions: We conclude that formation of SecTRAPs could contribute to the cytotoxicity seen upon exposure of cells to
electrophilic agents targeting TrxR. SecTRAPs are prooxidant killers of cells, triggering mechanisms beyond those of a mere
loss of thioredoxin reductase activity.
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Introduction
Mammalian thioredoxin reductases (TrxR, E.C. 1.8.1.9.) are
selenoproteins, i.e. they belong to the unique family of proteins
that contain a selenocysteine (Sec, U in one-letter code) residue [1–
3]. TrxR has, together with the principal substrate thioredoxin
(Trx), a wide range of functions in cells as a major reducing system
for DNA synthesis, redox regulatory functions and antioxidant
defense [4–9]. Three mammalian isoenzymes of TrxR have been
identified, namely the most abundant predominantly cytosolic
TrxR1 [1,3], mitochondrial TrxR2 [10–12] and TGR (thior-
edoxin glutathione reductase), the latter mainly expressed in testis
[13,14]. It should be noted, in the context of this study, that TrxR
proteins of other organisms such as bacteria, archaea, plants or
insects, are typically not selenoproteins. There is also a lack of
consensus for nomenclature of TrxR, sometimes abbreviated as
TR or TXNRD, with additional abbreviations occurring, e.g.
mitochondrial TrxR2 is the same enzyme as TR3 and TGR has
also been called TR2.
Mammalian TrxR1 is a homodimeric protein with the two
subunits arranged head to tail [15]. The first phases of the catalytic
cycle involve a transfer of electrons from NADPH via an enzyme-
bound FAD to a disulfide in the CVNVGC motif located in the N-
terminal domain, which is highly homologous to the mechanisms
of glutathione reductase and other members of the enzyme family
[15–19]. The electrons in TrxR1 are subsequently transferred
from the dithiol of the reduced CVNVGC motif to a selenenyl-
sulfide within the C-terminal -GCUG motif of the other subunit in
the dimeric holoenzyme. The selenenylsulfide is thereby reduced
to a selenolthiol, which can finally reduce the disulfide in the active
site of Trx or other substrates of TrxR [15,17,18,20]. Alternative
substrates for TrxR in addition to Trx encompass additional
protein disulfide substrates [21,22] as well as several low molecular
weight compounds, such as selenite [23], lipoic acid [24],
ascorbate [25] or quinones [26,27].
Sec is a selenium-containing analog to cysteine but a stronger
nucleophile with a low pKa, which makes Sec a highly reactive
amino acid [28]. The reactivity of Sec is essential for the native
catalytic activity of mammalian TrxR [18,20]. However, the
presence of Sec in TrxR at an easily accessible C-terminal position
renders the enzyme highly susceptible to irreversible inhibition by
derivatization of the Sec residue. Thus, TrxR can be inhibited by a
wide range of electrophilic compounds, many of them used in anti-
inflammatory or anticancer treatment. Such compounds include
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[27], platinum-containing anticancer drugs [31–34], and addi-
tional classical alkylating anticancer agents including nitrosourea
[34,35], melphalan and chlorambucil [34]. Endogenously pro-
duced electrophilic prostaglandin derivatives can also target the
enzyme [36].
It is easily conceivable that an inhibitor of TrxR would impose a
significant stress on cells due to the resulting inhibition of
thioredoxin-dependent reactions, the outcome of which would
depend upon the state and growth condition of the target cell
[5,6,9]. In addition, we previously found that derivatization of the
Sec residue in TrxR1 with electrophilic compounds may infer a
gain of function to the protein as a potent and direct inducer of cell
death [37]. A truncated form of TrxR1 lacking the two last amino
acids (–Sec-Gly) also induced cell death when introduced into cells,
while the full-length enzyme with normal enzymatic activity did
not [37]. Cytotoxic effects previously described for TrxR1 in the
form of GRIM-12 [38–42] seem to have been due to combinations
of TrxR1-dependent p53 activation and apoptosis induced by Sec-
deficient forms of TrxR1, as earlier discussed in detail [37].
The mechanism of the cell death triggered by cytotoxic forms of
selenium compromised TrxR1-derived proteins has hitherto been
unknown. In order to distinguish the unique properties of these
proteins from those of native TrxR1 enzyme, we have named
them SecTRAPs for selenium compromised thioredoxin reduc-
tase-derived apoptotic proteins, thereby referring to derivatives of
mammalian TrxR that have i, a compromised Sec residue, ii, no
Trx reducing capability and iii, the capacity to induce cell death by
a gain of function. The term SecTRAP also refers to the ‘‘trap’’ for
electrophilic compounds that the Sec residue in TrxR constitutes
due to its high nucleophilicity. In the present study, we have
analyzed the means by which SecTRAPs induce cell death.
We show here that not all forms of TrxR1 with a compromised Sec
residue show cytotoxic properties as SecTRAPs. Only forms of the
modified protein having an intact N-terminal CVNVGC motif and
being able to propagate NADPH oxidase activity could induce cell
death. This cell death had both apoptotic and necrotic features and it
correlated to an increased intracellular oxidative stress. The findings
suggest that the antioxidant selenoprotein TrxR1 under some
circumstances can be converted into a potent prooxidant killer of cells.
Materials and Methods
Chemicals and reagents
The BioPORTER Quick easy protein delivery reagent was
obtained from Gene therapy systems. Fetal calf serum (FCS) came
from Biotech Line AS, whereas Dulbeccos modified Eagle
medium, L-glutamine, phosphate buffered saline (PBS) and
PCR-primers were from Invitrogen. Antibiotics were purchased
from BIO-Whittaker Belgium. Ascorbic acid (Vit C), bovine serum
albumin (BSA), Cycloheximide, 29-(4-Ethoxyphenyl)-5-(4-methyl-
1-piperazinyl)-2,59-bi-1H-benzimidazole (Hoechst 33342), ju-
glone, propidium iodide (PI), tumor necrosis factor-a (TNF-a), a-
tocopherol (Vit E), 29,79-dichlorofluorescein (DCFH) and staur-
osporine (STS) came from Sigma-Aldrich Chemical Co. Cisplatin
(PlatinolH, cis-diamminedichloroplatinum; CDDP) came from
Bristol Myers Squibb. zVAD-fmk was obtained from Promega,
zDEVD-fmk from Biosource and zVDVAD-fmk from Calbio-
chem. AnnexinV-FITC fluorescence microscopy kit was pur-
chased from BD Biosciences.
Preparation of different forms of TrxR1 and SecTRAPs
The TrxR activity and estimated Sec content of the different
TrxR1 and SecTRAP preparations used in this study are
summarized in Table 1. The proteins were produced, purified
and analyzed as follows.
Recombinant rat TrxR1. Recombinant rat TrxR1 was
purified over 29,59-ADP-Sepharose (obtained from GE) from an
overproducing E.coli system using BL21(DE3) cells co-transformed
with the pET-TRSTER and pSUABC plasmids, essentially as
described previously [43,44].
Full-length rat TrxR1. The full-length Sec-containing rat
TrxR1 was enriched from the purified recombinant TrxR1
preparation using a phenyl arsine oxide (PAO) sepharose
column as described elsewhere [45,46].
Truncated rat TrxR1. The recombinant two-amino acid
truncated rat TrxR1 (having the C-terminal motif –Gly-Cys-
COOH instead of –Gly-Cys-Sec-Gly-COOH) was purified over
29,59-ADP-sepharose from an overproducing E.coli system using
BL21(DE3) cells transformed with the pET-TR plasmid (without
an engineered selenocysteine insertion sequence element),
resulting in production of truncated enzyme as described
previously [43]. For the determination of kinetic parameters, the
enzyme was produced in a BL21(DE3) gor
2 strain kindly provided
by Arne Holmgren, Karolinska Institutet.
Truncated human TrxR1. First, recombinant human
TrxR1 was purified over 29,59-ADP-sepharose from an
overproducing E.coli system using BL21(DE3) cells
cotransformed with pSUABC and a pET24d(+) plasmid
encoding the human TrxR1 open reading frame (isoform
TXNRD1_v1 [47]) in fusion with a bacterial-type SECIS
element (construct kindly provided from Dr. Antonio Miranda-
Vizuete), essentially following the procedure described for
expression and purification of recombinant rat TrxR1 (see
above). The two-amino acid truncated human TrxR1 was
subsequently collected from the initial flow-through fractions of
a PAO-sepharose purification scheme [45,46], using the purified
recombinant human TrxR1 as starting material.
Rat C59S/C64S mutant TrxR1. The pET-TRSTER
plasmid [43] was used as template in a PCR reaction using the
Table 1. Properties of the protein preparations used in this
study
Protein preparation
Specific
activity
a)
Estimated
Sec content
b)
units/mg % of protein species
Enzymatically active TrxR1 preparations
Recombinant rat TrxR1 as produced 15–20 30–50
Recombinant full-length rat TrxR1 34 90–100
SecTRAP preparations
rTrxR1-CDDP
c, ,0.6 30–50
Truncated human TrxR1 ,0.6 0
Truncated rat TrxR1 ,0.6 0
Mutant TrxR1 preparations
C59S/C64S mutant rat TrxR1 ,0.6 30–50
C59S/C64S-CDDP
d, ,0.6 30–50
a,The specific activity was determined with the standard DTNB assay [50] using
10 nM enzyme preparation.
b,Sec content was estimated from a combined assessment of specific activity,
75Se incorporation, production and purification method and comparisons to
earlier determinations [43–46,49].
c,Recombinant rat TrxR1 derivatized with cisplatin.
d,Mutant C59S/C64S rat TrxR1 derivatized with cisplatin.
doi:10.1371/journal.pone.0001846.t001
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upper primer 1: TTTAGGTATG GAGCCCACGT TCACA
GACGT TCCCCCG and complementary primer 2: CG
GGGGAACGT CTGTGAACGT GGGCTCCATA CCTAAA.
The PCR reaction was performed according to the protocol from
Stratagene and the PCR product was transformed into DHL-a
competent cells. A plasmid preparation containing the sequence-
confirmed C59S/C64S construct was further used for a TSS
transformation [48] together with pSUABC [43] into ORaa(DE3)
cells [49]. Colonies from this transformation were used to
overexpress the protein for purification. For this, cells were
cultured at 37uC in LB medium containing 50 mg/ml kanamycin,
34 mg/ml chloramphenicol and 0.01% arabinose. Recombinant
protein expression was subsequently induced by addition of IPTG
(500 mM) at OD 0.65 together with supplementation of selenite
(5 mM) and L-cysteine (100 mg/ml) and the cells were grown for
an additional 16 h at room temperature for production. The
overexpressed mutant protein was subsequently purified on a
29,59-ADP sepharose column (GE) from the cleared supernatant,
obtained after lysozyme treatment (400 mg/ml) and centrifugation,
essentially following the procedure described elsewhere [43,44,49]
and above for the other TrxR preparations.
After production and purification as described above, all rat and
human full-length or recombinant TrxR and SecTRAP prepara-
tions were subjected to desalting with NAP-5 columns (GE) for
buffer change to 50 mM Tris-Cl, 2 mM EDTA, pH 7.5 (TE-
buffer) and were kept in 220uC at a concentration of
approximately 1 mg/ml until use. Protein concentrations were
determined through the absorbance at 463 nm taking into account
an extinction coefficient of 11300 M
21cm
21 for the FAD
prosthetic group (which is present in both TrxR and SecTRAPs).
Derivatization with cisplatin. The rat C59S/C64S mutant
TrxR, or recombinant rat TrxR as control for derivatization, were
reduced with 0.5 mM DTT 20 min in room temperature before
addition of CDDP (200 mM). The samples were then incubated
for another 30 min, whereupon TrxR activity was measured in
both samples using the direct DTNB assay [50]. Complete
inhibition of the recombinant TrxR control sample was thereby
confirmed and used as an indication that conditions for full
derivatization of the Sec residue had been accomplished.
Subsequently both protein preparations were desalted over a
NAP-5 column equilibrated with TE-buffer and, to confirm
irreversible derivatization of the Sec residue with CDDP, an
additional DTNB assay was performed after the desalting step
using the recombinant TrxR1 sample as control, which showed
the expected lack of activity. Concentrations of these protein
samples were determined by the Bradford method according to
the protocol from BioRad using BSA as standard.
Enzyme activity determinations
Determination of kinetic parameters. NADPH consump-
tion measurements were performed by monitoring the change of
absorbance at A340 for 20 min using either a Hitachi-557 or
Schimadzu double beam spectrophotometer, essentially according
to protocols described previously [27,37,51,52]. Kinetic
parameters for juglone were determined as described earlier
[52]. The direct DTNB assay as a measure for mammalian TrxR1
activity was carried out as described [50] and parameters for the
insulin assay are described in Table 2.
Stopped-flow kinetics. The rapid reaction studies using
either truncated rat TrxR1 or full-length rat TrxR1 were
performed under aerobic conditions using a DX.17MV stopped-
flow spectrophotometer (Applied Photophysics) in 0.1 M K-
phosphate buffer solution (pH 7.0), containing 1 mM EDTA, at
25uC, essentially following the procedures described previously
[52]. The data were analyzed according to the single-exponential
fit.
Evaluation of a possible interaction between TrxR1 and
SecTRAP in vitro
Rat TrxR1 (5 nM), human wild-type Trx1 (10 mM), kindly
provided by Arne Holmgren, Karolinska Institutet, and NADPH
(200 mM) were incubated in TE buffer containing 1 mg/ml BSA
with different concentrations of truncated rat TrxR1 as a
SecTRAP preparation, added as indicated in the text. Direct
NADPH consumption was first assessed at A340 for 20 min (found
to be negligible), whereupon insulin (145 mM) was added. The
decrease at A340 was then followed for additional 30 min and
NADPH consumption was calculated from the slope of the initial
linear part of the curves. In addition, a similar assay was
performed using DTNB as substrate, instead of Trx and insulin.
For this, TrxR1 (20 nM), NADPH (0.8 mM) and varying
concentrations of SecTRAPs where mixed in a final volume of
50 ml TE-buffer containing 1 mg/ml BSA in microtiter plate wells
and then incubated 15 min at 37uC. Subsequently, 150 mlo fa
reaction mixture (2.7 mM EDTA, 67 mM Tris-Cl pH 7.4,
3.3 mM DTNB and 270 mM NADPH) was added and the
increase of absorbance at A412 was followed for 3 min.
Additional enzyme activity measurements
The NADPH consumption with subsequent estimation of free
thiols was performed in 200 ml reaction mixes using a 96-well plate
reader. In this assay, 10 nM of full-length or truncated rat TrxR1
was incubated with or without 10 mM human wild-type Trx1 and
145 mM insulin as indicated in the text, in 250 mM NADPH,
1 mg/ml BSA, 2 mM EDTA and 50 mM Tris-Cl (pH 7.5).
Juglone was dissolved in DMSO and used at the indicated
concentrations. Upon simultaneous addition of NADPH and
Table 2. No inhibition of TrxR1 activity in vitro by addition of
SecTRAPs
Ratio between
TrxR1:SecTRAPs
a,
Insulin
assay
b,
TrxR1 activity
DTNB assay
c,
TrxR1 only 20486317 24166125
10:1 26646941 2418666
1:1 27026532 25126141
1:10 26766868 2524690
1:50 24096211 32076248
1:2000
d, 22656247
d, n.d.
The values are mean6S.D. of six different measurements
a,The TrxR1 preparation in this experiments was full-length rat TrxR1 and the
SecTRAP preparation rat truncated TrxR1.
b,TrxR1 activity is given as turnover (min
21) calculated from the decrease at
340 nm detected in a microplate reader assay with 5 nM TrxR1, 0.5 nM-500 nM
truncated TrxR1 as SecTRAP, 10 mM Trx, 145 mM Insulin in 50 mM Tris-Cl,
2 mM EDTA, pH 7.4 and 200 mM NADPH.
c,TrxR1 activity calculated from the increase at 412 nm detected in a microplate
reader assay with 5 nM TrxR1, 2.5 mM DTNB in 50 mM Tris-Cl, 2 mM EDTA,
pH 7.4 and 200 mM NADPH based upon comparisons to standard curves
performed in normal quartz cuvettes with 1 cm light path length.
d,TrxR1 activity in insulin assay with 1:10 molar ratio of Trx1 (1 mM) and
truncated TrxR1 as SecTRAP (10 mM). The turnover (min
21) is calculated from
the decrease at 340 nm detected in a microplate reader assay using 5 nM
TrxR1, 145 mM insulin in 50 mM Tris-Cl, 2 mM EDTA, pH 7.4 and 200 mM
NADPH.
n.d.: not determined
doi:10.1371/journal.pone.0001846.t002
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at 340 nm over 30 min. Subsequently, 40 ml of each reaction was
used for estimation of free thiols, stopping the reaction by addition
of 160 ml 7 M GuHCl with 1 mM DTNB. Free thiol groups were
determined using absorbance at 412 nm and an extinction
coefficient of 13600 M
21cm
21. For determination of superoxide
formation the adrenochrome method was used, based upon
reduction of epinephrine by superoxide which can be quantified at
480 nm using an extinction coefficient of 4020 M
21cm
21,a s
described previously for studies of dinitrophenyl-derivatized TrxR
[51]. Here the adrenochrome assay was performed in a 96-well
plate reader with dual wavelength scan for the concomitant
determination of NADPH consumption (using 340 nm and an
extinction coefficient of 6200 M
21cm
21). For analysis whether the
BioPORTER reagent itself may be reduced or redox cycle with
TrxR or SecTRAPs, a reaction mixture containing 16 nM TrxR
or truncated TrxR1 as SecTRAP, respectively, was made in
complex with BioPORTER in the same ratios as in the regular cell
experiments. These protein mixtures where then assayed, in the
presence or absence of 5 mM juglone as positive control, in
300 mM NADPH, 2 mM EDTA and 50 mM Tris-Cl (pH 7.5)
and NADPH consumption was monitored at 340 nm for 15 min.
Potential superoxide production was also assessed using the
adrenochrome method (see above for details of this method).
Cell cultures and BioPORTER experiments
HEK293 (human embryonal kidney) cells (ATCC nr: CRL-
1573) were grown in RPMI whereas A549 (human lung
carcinoma) cells (ATCC nr: CCL-185) or HeLa (human cervical
cancer) cells (ATCC nr: CCL-2) were grown in Dulbeccos
modified Eagle medium with high or low glucose content,
respectively. All media were supplemented with 10% heat-
inactivated fetal calf serum, 2 mM L-glutamine, 100 units/ml
penicillin and 100 mg/ml streptomycin and the cells were cultured
in a humidified atmosphere of 5% CO2 at 37uC. For the different
treatments, cells were seeded in LabTecII chamber slides
(0.7 cm
2/well) at a density of 10,000 cells per well 16 h before
addition of protein/BioPORTER-complex, prepared according to
the manufacturers protocol and shortly described as follows. An
amount of 0.4 mg (for A549 or HEK293) or 0.2 mg (for HeLa)
TrxR1 or SecTRAPs preparations (as described in the text) in TE-
buffer (2 mM EDTA, 50 mM Tris-Cl, pH 7.5) was diluted in PBS
to a final volume of 20 ml subsequently added to a ‘‘quick easy’’
BioPORTER tube (Gene therapy systems) by pipetting up and
down 10 times to hydrate the dried compound. The protein/
BioPORTER preparation was then incubated for 5 min in room
temperature, briefly and gently vortexed for 5 s, whereupon it was
mixed with 390 ml of serum-free medium. Subsequently, the
mixture of 100 ml (for A549 or HEK293) or 200 ml (for HeLa)
protein/BioPORTER-complex and medium (typically correspond-
ing to a total amount of 100 ng TrxR or SecTRAP) was added to
each well, containing cells that had first been washed with serum-
free medium. To A549 and HEK293 cells, additional serum-free
medium (100 ml) was finally added, resulting in a total volume of
200 ml in each well, that had been seeded with 10,000 cells 16 h
prior to the experiment (see above). For assessment of concentra-
tion dependence, TrxR1 or SecTRAP was first diluted in TE-
buffer containing 1 mg/ml BSA in a volume so that the resulting
amount per well ranged from 1 pg to 100 ng TrxR1 or SecTRAP
as stated in the text, always added to each well in the BioPORTER
mix together with 100 ng BSA. In the experiments designed to
assess possible protection from excess full-length TrxR1, 10 ng
SecTRAPs per well were added together with the indicated
amounts of TrxR1, ranging from 1 ng to 100 ng.
In the experiments with antioxidants, A549 cells were
pretreated 1 h with 100 mM of ascorbic acid, 100 mM a-
tocopherol, or a combination of both, in serum-containing
medium. Fresh antioxidants (same concentrations) were subse-
quently added with the serum-free medium to the cells together
with the protein/BioPORTER-complex. Controls were always
made with TE-buffer, BioPORTER in absence of protein,
SecTRAPs in absence of BioPORTER,o rBioPORTER with only
BSA, as indicated in the text.
In all cell experiments, C-terminally two-amino acid-truncated
rat TrxR1 expressed as such in E. coli and purified over 29,59-ADP
sepharose (see above) was utilized as SecTRAP preparation, unless
stated otherwise.
Cell viability assessment
The extent of cell death was determined with assessment
through microscopy of fluorescent staining and morphology as
described previously [37]. Shortly, cells were washed once with
PBS after treatment for the indicated time with the BioPORTER
preparations (4 h unless stated otherwise). Subsequently 100 mlo f
10 mg/ml Hoechst 33342 in PBS was added to each well for blue
staining of all nuclei. After 15 min incubation at room
temperature 1 ml PI was added to a final concentration of
50 mg/ml for red staining of nuclei in (dead or dying) cells having
defective and permeable membranes. Cells were then incubated
for additional 5 min, whereupon they were washed once with
PBS. Using a Hamamatsu digital camera 4742-95 with Leica
DMRB microscope, three pictures were taken of the same field at
20-fold magnification using either white light or adapted with
filters for Hoechst fluorescence (excitation: 360 nm, emission:
460 nm) or PI fluorescence (excitation: 570 nM, emission:
610 nm). Cell death was subsequently evaluated with assessment
of the digital pictures, evaluating staining of the nuclei of a total of
700–1000 cells per well. Cells with blue-stained and PI-negative
normal looking non-condensed nuclei were considered viable,
whereas blue-stained cells with condensed nuclei or blue- as well as
red-stained cells were considered dying and/or dead, as described
previously [37] and also illustrated herein.
Assessment of phosphatidyl serine exposure using
Annexin-V staining
HeLa cells were seeded as described above and BioPORTER
alone, SecTRAP/BioPORTER-complex or 1 mM staurosporine
was added to the wells. After 3 h incubation, the cells were washed
once with cold PBS and then once more with 1x Annexin-V
binding solution, according to the protocol from the manufacturer
(BD Biosciences). Subsequently 150 ml of 1x Annexin-V antibodies
in binding solution were added to each well, followed by 15 min
incubation. After addition of 1.5 ml of PI (1 mg/ml) the cells were
incubated for additional 5 min, washed in Annexin-V binding
buffer, and positive Annexin-V staining was subsequently
visualized by fluorescence microscopy equipped with a filter for
fluorescein isothiocyanate (excitation: 490 nm, emission: 525 nm),
whereas any possible PI staining was assessed with the filter for
texas red (excitation: 570 nm, emission: 610 nm).
Analysis of caspase involvement
Cells were first seeded and grown as described above. For
caspase inhibition experiments, the cells were preincubated
30 min with the indicated inhibitors at concentrations and
conditions described in the text. Before treatment with protein/
BioPORTER-complex the cells were then washed once with serum-
free medium and new caspase inhibitor at the same concentration
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BioPORTER-complex in serum-free medium to the wells. Control
cells were treated in the same manner with preincubation in
serum-free medium, but with omission of caspase inhibitor. For
the incubations using an extended duration of preincubation,
serum-containing medium (final FCS concentration 10%) was
added after 3 h. At the indicated time points, cell viability was
evaluated as described above.
Experiment with cycloheximide
In order to analyze the requirement of protein synthesis for cell
death to occur, cells were seeded in LabTecII chamber slides
(10,000 cells per well) and incubated over night whereupon they
were pretreated 12 h with either cycloheximide (10 mM), TNF-a
(10 ng/ml), the combination of cycloheximide (10 mM) and TNFa
(10 ng/ml), or with only PBS as control, in all cases using medium
supplemented with 10% FCS. Subsequently the cells were washed
with serum-free medium before SecTRAP/BioPORTER-complex
was added and incubation was continued for 4 h, followed by cell
viability evaluation as described above.
Detection of ROS production
HeLa cells were seeded in LabTecII chamber slides (10,000
cells per well) and incubated for 16 h. Some cells were pretreated
1 h with 100 mM a-tocopherol, 100 mM ascorbic acid or 100 mM
of both compounds before addition of 100 ng of different protein/
BioPORTER-complexes as described above and indicated in the
figure legend. After 3 h incubation, cells were washed once in PBS
before 15 min incubation with 2 mM DCFH and 10 ug/ml of
Hoechst 33342. Cells were subsequently washed three times in
PBS before ROS production was detected by confocal microscopy
using filters for FITC, DAPI and rhodamine. All photographs of
DCF fluorescence at a certain magnification but with different
treatments were taken under identical incubation, excitation, and
exposure conditions.
Statistical analyses
Statistical analyses were performed with Prism 4 from GaphPad
Software, using one-way ANOVA and the Tukey-Kramer test for
determination of P values. The same software was used to draw
graphs of the analyzed data.
Results
Human and rat SecTRAPs induce cell death in human
A549 and HeLa cells
The aim of this study was to analyze the characteristic features
of SecTRAPs and to understand more about the cellular death
mechanisms triggered by these proteins. The previously observed
morphology of cells treated with SecTRAPs, showing PI uptake
and condensed DNA [37], was not enough to discriminate
between apoptosis and necrosis. Here we first confirmed that
nuclear condensation and PI uptake was triggered by SecTRAPs
in both A549 and HeLa cells, but not by full-length TrxR1, using
protein delivery into the cells with BioPORTER (Fig. 1A). When
treating HeLa cells with either SecTRAPs or staurosporine for
only 3 h, we observed phosphatidyl serine exposure as demon-
strated with Annexin-V staining. This apoptotic feature was
detected prior to major uptake of PI at this early time-point,
indicating that the cell membranes were still intact. The Annexin-
V staining upon treatment with SecTRAPs was stronger than after
treatment with 1 mM staurosporine, whereas no staining was
observed with only BioPORTER (Fig. 1B) ruling out the possibility
that the reagent as such affected the staining pattern. However, the
morphology of the cells treated with 1 mM staurosporine as a
positive control furthermore displayed cell membrane blebbing,
which was not seen after SecTRAP treatment (Fig. 1B).
In our previous study we introduced different preparations of
recombinantly expressed rat TrxR1 to a human lung adenocar-
cinoma cell line (A549) [37]. Here we found that both human and
rat SecTRAPs could effectively kill human HeLa and A549 cells
(Fig. 2A). We could not, however, detect any increased cell death
in HEK293 cells treated with SecTRAPs (not shown). We
therefore decided to use the rat truncated TrxR1 protein as a
SecTRAP preparation for our continued studies of cell death
triggered in A549 and HeLa cells because of significantly higher
yield in the recombinant expression system for rat TrxR1 than for
human TrxR1, which is probably due to different rare-codon
frequencies [43,53,54].
Low amounts of SecTRAPs induce cell death and
SecTRAPs are not direct inhibitors of the native
thioredoxin system
The cell death-inducing effect of SecTRAPs was pronounced
when 100 ng of protein was introduced to approximately 10,000
A549 or HeLa cells (Fig. 1 and Fig. 2A). A dilution series
illustrated a clear trend towards an increase in cell death at
treatment with as little as approximately 5 to 10 pg SecTRAP, but
at least 100 pg was needed to give a statistically significant
increased cytotoxicity using A549 cells treated for 4 h (Fig. 2B).
With a SecTRAP mass of 55 kDa, 100 pg amounts to about
100,000 SecTRAP molecules per cell, thereby sufficient to
provoke a significant increase of cell death in A549 cells, provided
that all of the added molecules were indeed delivered into the cells.
The killing effect was somewhat variable from experiment to
experiment, but under the conditions utilized here about 30–40%
dead or dying cells were typically observed after 4 h treatment
with 100 pg SecTRAPs or more (Fig. 2B). In line with these
findings, it should be noted that 10,000 A549 cells contain about
1–2 ng endogenous native TrxR1 and the results thereby suggest
that the cell death provoked by SecTRAPs in susceptible cells can
occur at rather low amounts, compared to the endogenous TrxR1
levels.
It was suggested that SecTRAPs could interact with enzymat-
ically active Trx1 endogenously present in the cells and thereby
inhibit Trx1-dependent reactions as part of the SecTRAP effect
[55]. Here we wished to experimentally assess such potential
interaction. For this, we first analyzed in vitro whether a 10-fold
molar excess of SecTRAPs over Trx1 and 2000-fold excess over
TrxR1 could inhibit the enzymatic activity of TrxR1 in a Trx1-
linked insulin reduction assay. We also studied the effects of
SecTRAPs in a direct TrxR1 activity assay using DTNB as
substrate. In neither case could we find evidence of an inhibition
of TrxR1 activity by an excess of SecTRAPs (Table 2). We then
analyzed whether A549 cells could be protected from SecTRAP-
induced cell death by the simultaneous addition of an excess of
enzymatically active full-length TrxR1. Using co-delivery of
10 ng SecTRAP with 100 ng TrxR, i.e. a 10-fold excess of TrxR
over SecTRAP protein, and about 50-fold excess of TrxR added
over the endogenous cellular level of TrxR, this indeed
counteracted the SecTRAP effect to some extent, while at
equimolar amounts or less of TrxR compared to SecTRAP no
protection was observed (Fig. 2C). These results (Table 2 and
Fig. 2C) suggest that SecTRAPs can provoke a cell death via a
mechanism not necessarily involving direct interactions with the
endogenous proteins of the thioredoxin system, but that the
thioredoxin system or at least TrxR1 may possibly have some
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SecTRAP level.
The cell death provoked by SecTRAPs occurs without
induction of novel protein synthesis
We next wished to study whether the cell death effect of
SecTRAPs required induction of novel protein synthesis. For this,
HeLa cells were preincubated with the protein synthesis inhibitor
cycloheximide for 12 h before treatment with SecTRAPs. As a
positive control for inhibition of protein synthesis, cycloheximide
was co-incubated with TNFa, which is a combinatory treatment
known to induce apoptosis in HeLa cells under these conditions
[56]. As expected, treatment with either the combination of
cycloheximide and TNFa, or with SecTRAPs alone, induced cell
death in HeLa cells (Fig. 3). However, cycloheximide had no effect
on the cell death provoked by SecTRAPs (Fig. 3), suggesting that
novel protein synthesis was not required for the cytotoxicity.
Caspase inhibitors can protect cells from SecTRAPs
The pan caspase inhibitor zVAD-fmk was first used to assess
whether the cell death provoked by SecTRAPs could be prevented
by general caspase inhibition. Both A549 and HeLa cells were well
protected against the effects of SecTRAPs when preincubated with
a high concentration (100 mM) of the general zVAD-fmk caspase
inhibitor (Fig. 4A). This result suggested that SecTRAPs may
provoke a cell death with apoptotic features, but high concentra-
tions of caspase inhibitor may also mask cell death by mitotic
catastrophe. However, a lower concentration of zVAD (25 mM)
was protective for up to 12 hours (not shown), as were more
specific caspase inhibitors. With two initiator caspases, caspase-8
and caspase-2, converging in activation of caspase-3 [57,58], we
decided to focus on these three caspases. A caspase-3 inhibitor
(zDEVD-fmk) at 25 mM almost completely prevented the cell
death provoked by SecTRAPs in either HeLa or A549 cells
(Fig. 4B). An inhibitor of caspase-8 (zIETD-fmk) at the same
Figure 1. SecTRAPs induce cell death and phosphatidyl serine exposure in human cancer cells. (A) Morphological features and staining
of HeLa and A549 cells after incubation for 4 h with BioPORTER (BP) alone, 100 ng full-length TrxR1/BioPORTER-complex, 100 ng SecTRAP/BioPORTER-
complex or 1 mM staurosporine (STS), as indicated. Hoechst 33342 was used to visualize the shape or condensation of the nuclei and PI was used as a
probe for lack of membrane integrity. Assessment of cell death was performed as described in the text. The percentage of cells denoted as dead,
counting a total of 700–1000 cells in this particular experiment, is also given in italics in the lower part of the figure. (B) Exposure of phospatidylserine
was evaluated after 3 h treatment of HeLa cells with either only BioPORTER, SecTRAP/BioPORTER-complex or 1 mM staurosporine, staining cells with
Annexin-V and PI as described in the text. Magnification was x 40 in all panels.
doi:10.1371/journal.pone.0001846.g001
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cells to about half, while it was highly protective in A549 cells. This
indicated that cell death upon exposure to SecTRAPs could
involve caspase-8, but the notable apoptosis seen in HeLa cells also
in presence of inhibitor suggested that an additional initiator
caspase could be involved. Notably, the caspase-2 inhibitor
Figure 2. Concentration dependent cell death induction by
SecTRAPs in two human cancer cell lines and the effects of
excess TrxR1. (A) HeLa and A549 cells were treated with 100 ng rat or
r
human SecTRAPs in the presence or absence of BioPORTER delivery
reagent, as indicated in the figure and described in the text. A
significant increase in cell death was seen in all cases where SecTRAPs
were incubated with the cells in the presence of BioPORTER as
compared to addition of SecTRAPs alone (***, p,0.001) (B) A SecTRAP
preparation (truncated rat TrxR1) at an amount of 0.1 pg-100 ng was
used for delivery into 10,000 A549 cells using BioPORTER, as described
in the text. The graph shows the determined cell death (mean
value6S.D.) triggered by each SecTRAP amount and significant
differences to control treatments are indicated, using as controls either
incubation with only TE buffer (white bar: n.s., p.0.05; *, p,0.05; **,
p,0.01; ***, p,0.001) or with BioPORTER alone (dashed bar: n.s.,
p.0.05; ##,p ,0.01; ###,p ,0.001). No significant difference in cell
death was seen comparing the two control treatments with each other.
(C) A549 cells were treated with 100 ng full-length TrxR1 or a mixture of
different amounts of TrxR1 with 10 ng SecTRAP using BioPORTER,a s
indicated in the figure. Differences in cell death were compared to
control cells either treated with TE buffer (white bar; **, p,0.01; ***,
p,0.001) or with only BioPORTER (dashed bar; ###,p ,0.001). No
statistically significant difference in cell death was seen between the
two control treatments or in comparisons of either control with the
treatment using 100 ng TrxR1 (n.s., p.0.05). In all experiments (A–C)
cells were incubated for 4 h with the separate treatments and were
subsequently stained with Hoechst 33342 and PI for evaluation of dead
cells as described in the text.
doi:10.1371/journal.pone.0001846.g002
Figure 3. Cell death by SecTRAPs is not dependent upon
induction of protein synthesis. HeLa cells were preincubated 12 h
with TNF-a, cycloheximide or a combination of TNF-a and cyclohexi-
mide, whereupon SecTRAP/BioPORTER-complex was added as indicated
and the cells were then incubated for additional 4 h. Cell death was
subsequently evaluated by staining with Hoechst and PI as described.
As a control experiment, an expected increase of cell death was seen
when cells were treated with the combination of TNF-a and
cycloheximide compared to treatment of either of these compounds
alone, showing that the cycloheximide treatment had inhibited protein
synthesis (see text). In contrast, cycloheximide had no effect on the cell
death provoked by the SecTRAP/BioPORTER treatment, as indicated in
the figure (n.s., p.0.05; *, p,0.05; **, p,0.01).
doi:10.1371/journal.pone.0001846.g003
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SecTRAPs in both A549 and HeLa cells, to the same total extent
as the inhibitor of caspase-3 (Fig. 4B). These results may indicate
that both caspase-2 and caspase-3 could be involved in the cell
death provoked by SecTRAPs.
SecTRAPs are efficient reductases with juglone in a
reaction dependent upon the N-terminal redox active
disulfide/dithiol motif
In our previous study we showed that SecTRAPs display very
low direct NADPH oxidase activity, i.e. in absence of other
substrates than NADPH and oxygen, apart from the case when
TrxR1 has been derivatized with dinitrohalobenzenes [37]. We
also found that glutathione reductase, having higher inherent
NADPH oxidase activity than the selenium-compromised forms of
TrxR1, lacked the capacity to induce cell death [37]. We thus
initially speculated that a direct prooxidant capacity of SecTRAPs
should not be the reason for the cell death induction. However, we
here hypothesized that SecTRAPs, still having a functional FAD
moiety and an intact N-terminal redox active CVNVGC motif
(see Introduction), could perhaps react with some endogenous
cellular substrate or target as a part of the apoptotic mechanism.
To test whether the N-terminal CVNVGC motif was important
for the SecTRAP effect we therefore generated a mutant where
the two cysteine residues in this motif were exchanged for serine
moieties. This protein was made to maintain an intact C-terminal
–GCUG motif and the incorporation of selenocysteine was
verified by
75Se labeling (not shown). We first performed in vitro
analysis of the NADPH consumption of the C59S/C64S mutant
compared to other TrxR1 or SecTRAP preparations, using the
quinone substrate juglone, which was previously studied with non-
modified TrxR1 and found to be reduced by the N-terminal
CVNVGC motif [27,52]. As expected the NADPH consumption
of the C59S/C64S mutant, either with the Sec residue intact or
with this residue derivatized with cisplatin, was negligible. We
concluded that the C59S/C64S mutant is, in principle, a
completely redox inert form of modified TrxR1. In contrast, a
SecTRAP preparation, here represented by the two-amino acid
truncated TrxR1 (with an intact N-terminal CVNVGC motif),
was found to efficiently reduce juglone, at a rate comparable to
that of full-length TrxR1. This finding was in line with our earlier
results, showing that juglone reduction can occur at the other
redox active sites of TrxR1 than the Sec-containing selenolthiol
motif [27,52]. It should again be emphasized in the context of the
present study that in spite of efficient juglone reduction, the
SecTRAP preparation completely lacked Trx reducing activity.
These results are summarized in Table 3.
Analyzing the stopped-flow kinetics of truncated rat TrxR1 as a
SecTRAP preparation as well as full-length rat TrxR1, we
observed that NADPH reduced the FAD moiety of both proteins
Table 3. Steady state kinetic properties of TrxR1, SecTRAPs
and the C59S/C64S mutant
Enzyme and substrate kcat (s
21) Km (mM) kcat/Km (mM
21s
21)
TrxR1 and juglone
a, 5.560.2 2.460.3 2.360.1
SecTRAPs and juglone
a, 6.560.6 4.461.1 1.460.3
C59S/C64S and juglone 0.460.01 15.562.2 0.02
TrxR1 and Trx
b, 27.5 2.5 11
SecTRAPs and Trx , 0.01
c, n.a. n.a.
C59S/C64S and Trx , 0.01
c, n.a. n.a.
a,kcat per active site and Km were calculated by following the NADPH
consumption as described in the text.
b,Values taken from [50] and adjusted to kcat per active site.
c,Measured in the insulin assay, under the same conditions as given in Table 2.
n.a., not applicable.
doi:10.1371/journal.pone.0001846.t003
Figure 4. Cell death induction by SecTRAPs is prevented by
caspase-2 and caspase-3/7 inhibitors. (A) shows that the cell death
provoked by SecTRAPs is significantly decreased upon preincubation of
either A549 or HeLa cells for 30 min with 100 mM of the general caspase
inhibitor zVAD before the SecTRAP treatment (**, p,0.01; ***,
p,0.001). In (B) HeLa or A549 cells were incubated 30 min with
25 mM of inhibitors for caspase-2 (zVDVAD-fmk), caspase-3 (zDEVD-fmk)
or caspase-8 (zIETD-fmk) before SecTRAP treatment. In all of these cases
a significantly lower cell death was observed, as indicated in the figure,
suggesting that the three caspases may be involved in propagating
the cell death triggered by SecTRAPs, as further discussed in the text
(*, p,0.05; **, p,0.01; ***, p,0.001).
doi:10.1371/journal.pone.0001846.g004
Cell Death by SecTRAPs
PLoS ONE | www.plosone.org 8 April 2008 | Volume 3 | Issue 4 | e1846at similar rates. The SecTRAP preparation formed the FAD-
thiolate charge-transfer complex typical of mammalian TrxR
enzymes, having an absorbance maximum at 540 nm [19,27],
with a rate of ,168 s
21 and the corresponding rate for full-length
TrxR1 was ,140 s
21 (Fig. 5A). In addition, juglone reduction,
using lower concentrations under steady state conditions, dis-
played an acceleration during reactions with either of the two
proteins, as found earlier for TrxR1 [27]. Apparent kinetic
parameters in the juglone reduction for the initial ,0–20 s time
period were in the same range for both proteins (Fig. 5B) and
determined here to kcat ,6s
21 and kcat/Km,1–2610
6 M
21s
21
(Table 3). These findings illustrate that SecTRAPs can propagate
rapid redox reactions with selected substrates, although they lack
the proper Sec-containing active site of TrxR1.
The effects of thioredoxin on the oxidoreductase activity
of SecTRAPs using juglone
Both Trx1 and juglone can compete as substrates for reduction
by full-length TrxR1. SecTRAPs however, can only reduce
juglone and not Trx1 (Table 3). We therefore wished to analyze
whether reduction of juglone by SecTRAPs could occur also in the
presence of Trx1, which would possibly suggest that SecTRAPs
can react with alternative substrates also in a cellular context
where Trx1 would be present. We found that Trx1 at a
physiological concentration (10 mM) could lower the juglone
reduction by truncated TrxR1 using low concentrations of juglone
(5 mM or less). However, 10 mM Trx1 had no effect on the
reduction of 50 mM juglone by truncated TrxR1, as demonstrated
by the same NADPH oxidation rate either in the presence or
absence of Trx1 and its disulfide substrate insulin (Fig. 5C, upper
panels, white bars). It should be noted that this activity was
dependent upon direct juglone reduction by the SecTRAP
protein, since this truncated enzyme has no activity with Trx1.
This fact was also illustrated by the lack of Trx-coupled insulin
reduction in the assay (Fig. 5C, lower left panel, white bars). The
properties of the SecTRAP protein were in sharp contrast to those
of full-length TrxR1, which has a preference for Trx1 as substrate,
being essentially unaffected by addition of low concentrations of
juglone in the presence of Trx1 and insulin. This was clearly
illustrated by the channeling of electrons from NADPH (Fig. 5C,
upper left panel, black bars) to production of free insulin-derived
thiols, formed through insulin disulfide reduction by Trx1 in the
reaction propelled by the TrxR1 enzyme (Fig. 5C, lower left panel,
black bars). However, the Trx1-reducing activity of full-length
TrxR1 was noticeably impaired at the higher concentration of
juglone (50 mM) through the effects of juglone as inhibitor and a
subversive substrate for the enzyme [27]. These results collectively
suggested to us that TrxR1 preferentially reduces Trx1 when
present, whereas SecTRAPs albeit not being able to reduce Trx1,
can still be active as oxidoreductases able to reduce other
substrates than Trx1. As we found next, this activity can confer
notable prooxidant properties, that also correlate to the cytotoxic
effects of SecTRAPs.
Superoxide is produced during reations with juglone
We detected superoxide production during juglone reduction,
by either SecTRAPs or TrxR1, as assessed with the adrenochrome
method. Interestingly, addition of epinephrine also increased the
rate of NADPH consumption (Fig. 5D). Addition of excess SOD
completely abolished the adrenochrome formation, confirming
that superoxide was formed (Fig. 5D). These findings were possibly
suggestive of one-electron reduction of juglone, producing
superoxide, which would be in contrast to the predominant two-
electron reduction mechanism found earlier using 1,4-benzoqui-
none as a quinone substrate for TrxR1 [27]. As reported in our
earlier study, TrxR1 is an efficient reductase for several quinones
in addition to juglone, i.e. in the absence of Trx1, including 9,10-
phenanthrene quinone [27]. The latter substrate is reduced solely
by the Sec-containing C-terminal active site [27]. Accordingly, we
found here that SecTRAPs are completely inactive in reduction of
9,10-phenanthrene quinone (not shown), in contrast to their
efficient reduction of other substrates such as juglone.
The cell death provoked by SecTRAPs correlates to the
prooxidant capacity
When the different TrxR1 or SecTRAP preparations that we
had analyzed for juglone reduction (Table 3) were introduced into
A549 cells, we found that the C59S/C64S mutants could not
provoke cell death at any higher extent than non-compromised
TrxR1 or the control using only BioPORTER treatment, in
contrast to the cell-killing SecTRAP capacity of either TrxR1 that
had been derivatized with cisplatin, or of truncated TrxR1 (Fig. 6).
This showed that an intact CVNVGC motif of the selenium-
compromised forms of TrxR1 was required for SecTRAP
properties. Considering the different enzymatic activities of the
pure protein preparations (Table 3, Fig. 5) in line with their cell
killing capacity (Fig. 6), it became apparent that only those TrxR1-
derivatives having the capacity to support efficient reduction of
juglone and at the same time lacking Trx1 reducing activity, were
functional as SecTRAPs. This suggested to us that in a cellular
environment, non-derivatized native TrxR1, albeit having qui-
none reductase activity in vitro as both found here (Table 3, Fig. 5)
and previously shown [27], may easily be saturated by the
endogenous Trx1 substrate and thus mainly propagate Trx1-
dependent cellular functions. SecTRAPs, in contrast, may kill cells
due to their predominant prooxidant capacity (Fig. 5D), provided
that there is a cellular substrate that could take the place of juglone
used in our in vitro assays.
Pretreatment with antioxidants would likely protect cells against
the toxic effects of SecTRAPs if a prooxidant effect is the
mechanism for cell death induction. To test this, we preincubated
cells with either water-soluble ascorbic acid (Vit C), lipid soluble a-
tocopherol (Vit E), or a combination of both, with subsequent
assessment of the induction of cell death by SecTRAPs. The
background cell death with only antioxidant treatment was 5–10%
and increased marginally to 10–15% together with BioPORTER.
Upon treatment with SecTRAPs in the absence of antioxidants the
cell death reached the same level as seen previously, but this effect
could indeed be blocked by either antioxidant alone (Fig. 7).
Interestingly, however, the combinatory treatment of both
antioxidants together with the SecTRAP/BioPORTER-complex
resulted in a similar level of cell death as that seen with SecTRAP/
BioPORTER alone, while the combination of both antioxidants
together with only BioPORTER but without SecTRAP, had no
such effect (Fig. 7). These results suggested that antioxidant
treatment can indeed prevent SecTRAP-provoked cell death, but
also that SecTRAPs can propagate a cytotoxicity derived from the
simultaneous treatment with ascorbate and a-tocopherol.
To further analyze whether oxidative stress was indeed
provoked in these experiments, we subsequently used DCFH as
a probe in experiments treating HeLa cells with either TrxR1 or a
SecTRAP preparation, in combination with the antioxidant
compounds. Cells treated with SecTRAPs displayed an intensive
green fluorescence of DCF, which was not observed after
treatment with TrxR1 or BioPORTER alone (Fig. 8, left three
panels). The DCF signal was quenched after treatment with either
ascorbate or a-tocopherol, although DCF fluorescence was
detectable in some cells after treatment with ascorbate (Fig. 8,
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PLoS ONE | www.plosone.org 9 April 2008 | Volume 3 | Issue 4 | e1846Figure 5. Both SecTRAPs and TrxR1 are efficient in reducing juglone and thereby produce superoxide. In (A) the formation of FAD-
reduced disulfide charge transfer complex by NADPH (80 mM) in a SecTRAP preparation (truncated TrxR1, 16 mM subunit) and full-length TrxR1
(12 mM subunit) was analyzed with stopped-flow spectroscopy at 540 nm, showing similar kinetics for both enzymes. In (B) Michaelis-Menten kinetics
for both full-length (filled symbols) and truncated (open symbols) TrxR1 using juglone as a substrate is demonstrated. In (C) it is shown that Trx1 and
juglone compete for the reduction by full-length TrxR1 (filled bars) but that truncated TrxR1 (open bars) can only use juglone and not Trx1 as a
substrate. This is illustrated from the initial NADPH consumption rate (0–200s) followed at 340 nm with or without Trx1 and insulin (upper panels).
After 30 min of reaction, the number of exposed free thiols was determined (lower panels) in order to estimate to which extent the electrons from
the NADPH oxidation were passed on to Trx1 and subsequently to insulin. The juglone concentration is indicated at the x-axes and each bar
represents the mean6S.D. of three measurements. In (D), the reduction of juglone (5 mM) catalyzed by 10 nM SecTRAP (truncated TrxR1, left panel)
or full-length TrxR1 (right panel) is shown following the consumption of NADPH (initial concentration 250 mM) by the decrease in absorbance at
340 nm (open symbols). Concomitantly, superoxide formation was detected at 480 nm with the adrenochrome method using 2 mM epinephrine
(filled symbols). The formation of adrenochrome was completely inhibited by addition of 5 U SOD (circles), which also reduced the elevated NADPH
consumption seen upon addition of only epinephrine (squares).
doi:10.1371/journal.pone.0001846.g005
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both antioxidants together with SecTRAPs gave a strong DCF
signal, yet in a different pattern compared to SecTRAPs alone
(Fig. 8). This finding substantiated that SecTRAPs could
propagate an oxidative stress, either directly in cells or in concert
with the combination of ascorbate and a-tocopherol as used
herein. The intensity of DCF fluorescence thus correlated well
with the observed cell death using the same treatments (cf. Fig. 7
and Fig. 8).
Discussion
Here we have found that cell death provoked by certain forms
of selenium compromised mammalian TrxR1 (SecTRAPs) shows
both apoptotic features, such as Annexin-V staining and
protection by caspase inhibitors, as well as necrotic features, such
as lack of membrane blebbing or nuclear segmentation and an
extensive direct PI uptake, the latter which indicated that cellular
membrane integrity was rapidly lost. Those findings in combina-
tion with the intracellular ROS production triggered by Sec-
TRAPs, as shown by DCF fluorescence and the protection from
cell death by antioxidants, collectively show that the selenoprotein
TrxR1, a key player in antioxidant defense, can be converted into
a potent prooxidant killer of cells when its highly reactive Sec
residue becomes compromised.
The notion that SecTRAPs trigger cell death, at least in part, by
a provoked oxidative stress is compatible with several earlier
observations. It agrees well with the fact that DNCB as well as
juglone are compounds that target and inhibit cellular TrxR1 with
concurrent induction of a cell death, showing necrotic features but
also involving caspase-3/7 activation and being strikingly different
in properties compared to the cell death triggered by staurosporine
[52]. Formation of SecTRAPs may possibly also be part of the
mechanism for induction of apoptosis by the TrxR1-specific
inhibitor auranofin in both cisplatin-sensitive and –resistant cancer
cells, shown to be related to production of reactive oxygen species
as well as the levels of thioredoxin reductase [59]. It was
furthermore shown that targeting of TrxR1 by electrophilic
prostaglandin derivatives induces a different type of cell death,
than that resulting from siRNA-mediated knockdown of TrxR1
[36,60]. In addition, derivatization of TrxR1 by cisplatin with
formation of SecTRAPs may be one explanation for the ROS
formation and triggering of apoptotic pathways in cytoplasts
treated with cisplatin, where DNA damaging effects evidently
cannot play a role [61]. SecTRAP formation could potentially be a
factor contributing to the cytotoxic effects of several known TrxR1
inhibitors, such as curcumin [62], arsenic trioxide [30], 4-hydroxy-
2-nonenal [63], or some of the additional TrxR1 inhibitors
discussed elsewhere [6,64–66]. It is noteworthy that TrxR1
inhibitors often result in more pronounced oxidative stress and
cytotoxicity than knockdown of TrxR1 using siRNA. The latter
seems to result in slower cell growth, but without clear signs of
oxidative stress or apoptosis [67,68] and, as recently shown,
without evident oxidation of Trx1 [69]. In contrast, treatment of
cells with one inhibitor of TrxR1 (monomethylarsonous acid) can
lead to Trx1 oxidation and ROS formation whereas another
inhibitor (aurothioglucose) did not show such effects, in spite of
about 90% reduction in the total cellular TrxR activity in both
cases [69]. Reasons for different effects between use of different
TrxR1 inhibitors or in comparison to TrxR1 knockdown
experiments could, naturally, include potential interactions of
the inhibitors with additional cellular targets apart from TrxR1.
Another explanation could however also be that formation of
Figure 6. C59S/C64S mutant SecTRAPs cannot induce cell
death in A549 cells. A549 cells were treated with 100 ng of the C59S/
C64S mutant rat TrxR or native rat TrxR1 preparations, with or without
cisplatin (CDDP) derivatization of the Sec residue, using BioPORTER, as
indicated in the figure and described further in the text. Cell death was
significantly increased after treatment with truncated TrxR or TrxR1
derivatized with cisplatin compared to control using only BioPORTER,
whereas the other proteins gave no significant difference in cell death
compared to the control (n.s., p.0.05; *, p,0.05; **, p,0.01).
doi:10.1371/journal.pone.0001846.g006
Figure 7. Either a-tocopherol or ascorbic acid can prevent cell
killing by SecTRAPs but not the combinatory treatment. A549
cells were preincubated for 1 h with a-tocopherol (100 mM), ascorbic
acid (100 mM) or a combination of the two compounds, as indicated in
the figure. SecTRAP/BioPORTER-complex was subsequently added to
the cells, which were then incubated for additional 4 h before analysis
of cell death as described in the text. A significant increase in cell death
compared to non-treated cells (***, p,0.001) or cells treated with only
BioPORTER (##,p ,0.01, ###,p ,0.001) was seen in cells treated with
SecTRAPs either in absence of the antioxidant compounds or together
with the combination of both a-tocopherol and ascorbic acid. All other
treatments lacked a significant difference in cell death compared to
either of the two controls (p.0.05).
doi:10.1371/journal.pone.0001846.g007
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those inhibitors specifically targeting the Sec residue to the
enzyme. This can, as shown herein, result in a gain of function of
the protein that can provoke oxidative stress and cell death,
thereby not solely being the result of diminished TrxR1 activity.
We found earlier that glutathione reductase (GR), having higher
inherent NADPH oxidase activity in vitro than SecTRAPs, could
not provoke cell death [37]. The likely reason should be that the
NADPH oxidase activity of GR is suppressed in a cellular context,
where the enzyme would easily be saturated with its natural
substrate glutathione. It should furthermore be noted that the
protein surface charge distribution patterns of GR and TrxR1 are
strikingly different from each other; this was suggested to explain
the different substrate specificities between these two enzymes,
even upon removal of the selenolthiol motif in TrxR1, although
the two enzymes are otherwise closely related in overall domain
configuration [70]. This difference may be part of the explanation
why TrxR1, or SecTRAPs, are about one order of magnitude
more efficient than GR in reduction of several quinone substrates
[27].
Our findings that SecTRAPs can be potent prooxidant
enzymes, although they completely lack the native Trx1 reducing
capacity of TrxR1, could explain much of their toxic properties.
We have not yet identified any cellular endogenous substrate(s)
that interact with SecTRAPs. However, the findings with the
model substrate juglone clearly demonstrated that SecTRAPs have
the capacity to become potent superoxide-producing NADPH
oxidases, also in the presence of physiological concentrations of
Trx1, provided that intracellular substrates exist at sufficient
concentration together with which SecTRAPs can propagate
prooxidant reactions. The prominent oxidative stress seen upon
treatment of cells with SecTRAPs, as illustrated by the increased
DCF fluorescence and the protective effects of antioxidants,
suggest that such intracellular substrates exist.
The observation that SecTRAPs could propagate intracellular
ROS production and cell death upon the combinatory treatment
with ascorbic acid and a-tocopherol, whereas either of the two
compounds alone protected the cells, was an intriguing finding. It
can likely be explained by the redox properties of these compounds
in connection with the properties of SecTRAPs and the finding
further supports our view that directly SecTRAPs propagate
oxidative stress, coupled to some hitherto unidentified cellular
substrate(s). It should be noted that antioxidant compounds, like
ascorbate and a-tocopherol, all have the inherent capacity to act as
prooxidants because they easily form radical compounds, with their
cellular effects thereby being a matter of concentration and the
microenvironment withinwhichtheyact. IfSecTRAPspromotethe
initiating oxidative event and ascorbic acid and a-tocopherol are
present at high equal concentrations, this may potentially first lead
to the formation of ascorbyl radicals, which in turn may react with
a-tocopherol to form tocopheryl radicals. Thereupon the electrons
can be transferred to subsequent cellular compounds, induce
propagation of radical formation and give rise to the observed
oxidative stress. This potential reaction, from SecTRAPs over
ascorbate to tocopheryl radical formation, should be amplified
when a-tocopherol is added concomitantly with ascorbic acid and
Figure 8. HeLa cells treated with SecTRAPs show an increased production of reactive oxygen species that was quenched by either
a-tocopherol or ascorbic acid but not by the combinatory treatment. HeLa cells were treated with BioPORTER, TrxR1/BioPORTER or
SecTRAPs/BioPORTER for 3 h as indicated in the figure, whereupon the images of the cells stained with the ROS-sensitive marker DCFH were taken, as
described in the text. The cell nuclei were counterstained with Hoechst 33342. Ascorbic acid (Vit C) and/or a-tocopherol (Vit E) was added 1 h in
advance to the cells before treatment. Two distinct experiments with two samples in each treatment were performed with similar results and
representative images of the observed staining patterns are shown. The three right-most pictures displaying the intracellular patterns of DCF
fluorescence are shown at higher magnification than the three panels to the left displaying the overview of DCF fluorescence in control cells or in
cells treated with either TrxR1 or SecTRAPs together with BioPORTER.
doi:10.1371/journal.pone.0001846.g008
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ascorbyl radicals that are formed through the prooxidant effects of
SecTRAPs, could easily dismutate into one ascorbate and one
dehydroascorbate molecule, thereby acting as chain-breaking
antioxidant. If a-tocopherol alone is added in excess, this may
potentially protect cellular lipids from oxidative damage, but
SecTRAPs are probably less likely to induce tocopheryl radicals
by direct interactions, while in contrast a direct reaction with
ascorbic acid is indeed plausible. Interestingly, dehydroascorbate
formed from the ascorbyl radical dismutation can be reduced back
to ascorbic acid by TrxR1. For further discussions on the web of
interactions and reactions between TrxR1, ascorbic acid and a-
tocopherol, see an earlier review on the subject [8].
In this study, we used a two-amino acid C-terminally truncated
form of TrxR1 as the major model protein for studies of
SecTRAPs. Such truncated TrxR1 could perhaps be produced
in certain cells during translation by a truncation at the Sec-
encoding UGA codon. However, the interplay between UGA-
directed Sec insertion and translational termination is far from
fully understood in mammalian cells and the UGA-truncated form
of TrxR1 has not yet been conclusively demonstrated in analyses
of selenium-starved tissue. Only direct demonstration of the two-
amino acid truncated TrxR1 species purified from selenium-
depleted tissues would answer whether such protein species may
be formed under natural conditions of selenium depletion. To our
knowledge, no studies have yet been published demonstrating
endogenous production of the truncated enzyme in mammalian
tissues. Evidence for production of a truncated TrxR1 species was
reported for NCI-H441 cells [71], while in other liver or kidney-
derived cell lines clear evidence for such production at selenium
depletion could not be seen [72]. The toxicity of SecTRAPs to
A549 and HeLa cells could possibly explain prior difficulties
encountered in attempts to establish a stable TrxR1-overexpress-
ing cell line. After several unsuccessful attempts in different tumor
cell lines (Jurkat, HeLa, U1285), an overproducing stable
transfection was finally achieved in HEK293 cells, as reported
elsewhere [73], which is a cell line that we found to be resistant to
SecTRAPs. It is possible that the difficulty to stably overexpress
TrxR in several different cell lines, may have been due to the fact
that under such overproducing conditions, UGA-truncated forms
of TrxR1 (i.e. SecTRAPs) are formed, while the HEK293 cells in
which the overproduction was successful are resistant to Sec-
TRAPs by a mechanism yet to be elucidated. Although it is not
clear whether cells or tissues may become exposed to truncated
TrxR1 under certain cases of selenium limitation, formation of
SecTRAPs can nonetheless occur through the direct derivatization
of the Sec residue of TrxR1 by electrophilic compounds, either
endogenously produced in cells, exposed in the form of xenobiotics
or environmental contaminants, or purposely given in the form of
alkylating drugs.
Here we showed that SecTRAPs, devoid of the natural Sec-
containing active site of TrxR1, could still have their FAD cofactor
efficiently reduced by NADPH. Upon reduction by NADPH,
SecTRAPs could also form the charge-transfer complex between
the FAD moiety and the CVNVGC redox active disulfide/dithiol-
containing site. The fact that the cell-killing SecTRAP properties
evidently depend upon an intact FAD/CVNVGC-containing
redox active motif and correlate to a prooxidant capacity has
additional implications. A potential drug or compound that would
inhibit the redox activity of this N-terminal motif, and thereby
block the reductive half reaction of TrxR1-derived protein, would
according to his notion not give rise to the formation of SecTRAPs.
However, such potential drugs may still have major effects on
cellular function as a result of the lowered capacity of the
thioredoxin system, reminiscent to the effects of knocking down
TrxR1 expression by siRNA [60,68,74,75]. This emphasizes the
delicate balance between different cellular effects that can be
governed by either an intact thioredoxin system, by a loss of
thioredoxin reductase activity, or by the formation of SecTRAPs.
This concept is summarized in the scheme shown in Figure 9.
The pronounced protection of the cells by inhibitors of caspase-
3/7 or caspase-2, and partially caspase-8, indicated that the
apoptotic machinery was required for cell death to occur in
connection with the oxidative stress triggered by SecTRAPs. The
general features of the cell death found here, with both caspase-3
and caspase-8 involvement and signs of both apoptosis and
necrosis, are in fact typical for cell death induced by oxidative
stress [76]. Regarding caspase-2, recent findings have shown that
this caspase when activated can induce apoptosis by directly
promoting the release of cytochrome c from mitochondria [77,78].
We have attempted to detect mitochondrial release of cytochrome
c after treatment with SecTRAPs, however with inconclusive
results. It should also be noted that it was recently shown that Ac-
VDVAD-CHO, commonly used as caspase-2 inhibitor, may also
inhibit caspase-3 [79]. Moreover, we also studied the effects of a
caspase-9 inhibitor (z-LEHD-fmk) but with intermediate and
inconclusive results (not shown). Therefore, taken together we do
not know at present to which extent the SecTRAP-induced cell
death involves caspase-2 activation, release of cytochrome c from
the mitochondria or caspase-9 activation. We have been limited in
our analyses by the low amount of cells used in experiments
employing the BioPORTER protein delivery approach. We have
attempted to construct stably transfected HeLa cells for condi-
tional overexpression of the two-amino acid truncated TrxR1 but
were not successful to do so, potentially because of the toxic effects
of a low basal expression of truncated TrxR1 (S. Prast-Nielsen and
E. Arne ´r, unpublished results). Future studies with other
approaches are clearly needed for more detailed analyses of
signaling events such as cytochrome c release from the mitochon-
dria or direct detection of caspase activation.
Based upon the results presented in this study, we conclude that
SecTRAPs, produced by C-terminal truncation of TrxR1 or by
chemical derivatization of its Sec residue, are potent inducers of a
cell death that involves both apoptotic and necrotic features in line
with increased intracellular ROS production. The effect was rapid
and did not require induction of protein synthesis. The properties
of SecTRAPs obviously add another level of complexity to the
thioredoxin system. It is becoming increasingly evident that the
thioredoxin system is of major importance for cancer development
and as a target for anticancer therapy [6,64,66]. Within that
context, it is plausible that formation of SecTRAPs may play a role
for some of the observed effects e.g. seen upon use of alkylating
drugs in cancer treatment. Further studies are needed in order to
fully understand both the exact molecular mechanisms by which
SecTRAPs trigger apoptosis in cells and the potential physiological
or clinical importance of the formation of these proteins.
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